After chronic subdural hematoma drainage, who benefits from embolization?

After chronic subdural hematoma drainage, who benefits from embolization?

When an older patient recovers after drainage of a chronic subdural hematoma, the possibility of recurrence still matters. Embolizing the middle meningeal artery targets vessels in the hematoma membrane that can sustain bleeding. The clinical question is whether adding this procedure prevents a return of symptoms often enough to justify its risks. Two randomized trials help frame that conversation. [1] [2]

What the Canadian trial found

EMMA-Can enrolled adults at nine Canadian centers. Each had a symptomatic collection on one side measuring at least 10 mm and had undergone surgical drainage. Investigators randomized 192 participants. Among the 186 who completed the trial, four of 93 patients receiving liquid embolization within 72 hours of surgery had symptomatic, CT-confirmed recurrence at 90 days (4.3%). In the drainage-only group, 26 of 93 did (28%). The absolute reduction was 23.7 percentage points (95% confidence interval 13.9 to 34.1). [1]

The endpoint required symptoms as well as imaging. It therefore answers a different question from whether a residual collection is visible on a follow-up scan. Serious adverse events occurred in eight embolization patients and five controls. Those small numbers leave substantial uncertainty about differences in safety. [1]

Why estimates differ across centers

The French EMPROTECT trial enrolled 342 surgical patients with a recurrence or a first episode judged at high risk of recurrence. It used microparticles and assessed recurrence at six months. The outcome occurred in 14.8% with embolization and 21.0% with standard care, a difference that did not reach statistical significance. Patient selection, embolic material and outcome definitions differed. The trials cannot establish which material works better. [1] [2]

What to take into practice

For the postoperative discussion, neurosurgery and neurointervention can review the patient’s recurrence risk, the center’s outcomes and the additional procedural risk together. The 2026 SNIS guidance supports adjunctive embolization to reduce recurrences requiring another intervention. Patients who need urgent decompression still need a surgical assessment. [2] [3]

Browse the MedBay catalogue for Radiology & Interventional Radiology

Sources

Evidence checked on 21 November 2026.

[1] Shankar et al. EMMA-Can randomized clinical trial, JAMA (2026-04-30).

[2] Shotar et al. EMPROTECT randomized clinical trial, JAMA (2025-06-05).

[3] SNIS Standards and Guidelines Committee. Middle meningeal artery embolization in chronic subdural hematoma, Journal of NeuroInterventional Surgery (2026-04-29).

Leave a Reply

Your email address will not be published. Required fields are makes.

Select your currency
USD United States (US) dollar